MARKET

ENDP

ENDP

Endo Intl Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6201
-0.5399
-46.54%
After Hours: 0.6200 -0.0001 -0.02% 19:59 05/18 EDT
OPEN
1.130
PREV CLOSE
1.160
HIGH
1.140
LOW
0.3615
VOLUME
55.15M
TURNOVER
1.20M
52 WEEK HIGH
7.07
52 WEEK LOW
0.3615
MARKET CAP
145.79M
P/E (TTM)
-0.2126
1D
5D
1M
3M
1Y
5Y
6 Stocks Halted In Wednesday's Session: Here's Why
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and bring order to the markets.
Benzinga · 7h ago
What Is Happening With Endo Shares Today
Benzinga · 9h ago
Endo in talks with creditors for debt restructuring - WSJ
Endo International (NASDAQ:ENDP) has begun negotiations with its lenders and senior bondholders seeking a possible reorganization of more than $8 billion of its debt, The Wall Street Journal reported on
Seekingalpha · 12h ago
BRIEF-Endo International Begins Negotiations With Creditors About Possible Restructuring Of More Than $8 Bln In Debt - WSJ
reuters.com · 13h ago
Glenview Capital added Valvoline, exited Amgen, expanded position in US Foods, narrowed stake in Bausch Health
Larry Robbins and Mark Horowitz owned fund, Glenview Capital in its recent 13F filing disclosed newly acquired stakes in Valvoline (VVV) with 1.7M shares, Berkeley Lights (BLI) with 1.19M shares,
Seekingalpha · 1d ago
Is it Still Worth Keeping Your Endo International (ENDP) Shares?
Miller Value Partners, an investment management firm, published its “Income Strategy” first quarter 2022 investor letter – a copy of which can be downloaded here. The Miller Income Strategy returned -10.08% for the first quarter, while the unmanaged high-y...
Insider Monkey · 2d ago
Endo Int'l. Shareholder The Buxton Helmsley Group Issues Open Letter To Shareholders Related To 'corporate malfeasance and false statements of financial position'
The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Endo
Benzinga · 5d ago
Endo International slumps 15%, BMO Capital cuts PT to $2
Endo International (NASDAQ:ENDP -19.0%) price target cut to $2 from $4 by BMO Capital Markets analyst Gary Nachman, maintains market perform rating. This implyies a 41% increase from last price. Company reported earnings and
Seekingalpha · 05/09 16:08
More
No Data
Learn about the latest financial forecast of ENDP. Analyze the recent business situations of Endo Intl Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Underperform

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
40.00%Hold
60.00%Under-perform
0.00%Sell
Analyst Price Target
The average ENDP stock price target is 1.333 with a high estimate of 2.000 and a low estimate of 1.000.
High2.000
Average1.333
Low1.000
Current 0.6201
EPS
Actual
Estimate
-0.010.250.520.78
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 295
Institutional Holdings: 201.70M
% Owned: 85.79%
Shares Outstanding: 235.11M
TypeInstitutionsShares
Increased
63
16.94M
New
50
11.79M
Decreased
57
14.41M
Sold Out
29
2.13M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.80%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Non-Executive Chairman/Independent Director
Mark Barberio
President/Chief Executive Officer/Director
Blaise Coleman
Chief Financial Officer/Executive Vice President
Mark Bradley
Executive Vice President
Patrick Barry
Executive Vice President
Matthew Maletta
Senior Vice President/Chief Accounting Officer/Controller
Jack Boyle
Independent Director
Jennifer Chao
Independent Director
Shane Cooke
Independent Director
Nancy Hutson
Independent Director
Michael Hyatt
Independent Director
William Montague
Independent Director
M. Christine Smith
No Data
No Data
About ENDP
Endo International Public Limited Company is a generics and specialty branded pharmaceutical company. The Company operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL, EDEX and LIDODERM, and others. Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection. Its Generic Pharmaceuticals segment consists solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic and sprays.

Webull offers kinds of Endo International PLC stock information, including NASDAQ:ENDP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENDP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENDP stock methods without spending real money on the virtual paper trading platform.